Chronic Myeloid Leukemia (CML): Background, Pathophysiology, Epidemiology
CML is caused by the BCR::ABL1 fusion gene created by the Philadelphia chromosome translocation, which drives uncontrolled granulocytic proliferation.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR::ABL1 fusion protein resulting from the Philadelphia chromosome translocation. It progresses through chronic, accelerated, and blast phases, and frontline therapy with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib has dramatically improved survival.
Early molecular diagnosis and targeted TKI therapy transform CML from a fatal disease to a chronic, treatable condition with near‑normal life expectancy for most patients.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Can natural killer cells cure leukemia?
- MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
- Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
- Immunotherapy for leukemia may change the bone marrow environment, cancer researchers find
- Next-generation CAR‑T therapy for acute myeloid leukemia: bridging innovation with clinical translation